Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 12, 2015

Primary Completion Date

May 22, 2018

Study Completion Date

May 22, 2018

Conditions
Hepatitis B
Interventions
BIOLOGICAL

INO-1800

INO-1800 delivered by EP

BIOLOGICAL

INO-9112

INO-9112 delivered by EP

DRUG

Nucleos(t)ide Analogue Treatment

Continued treatment with nucleos(t)ide analogue

Trial Locations (22)

112

Taipei Veterans General Hospital, Taipei

333

Chang Gung Memorial Hospital, Linkou District

807

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

1023

Auckland City Hospital, Auckland

1605

The Medical City, Pasig

2747

Nepean Hospital, Kingswood

4101

Mater Adult Hospital, South Brisbane

5000

Royal Adelaide Hospital, Adelaide

10002

National Taiwan University Hospital, Taipei

10029

Mount Sinai - PRIME, New York

10700

Siriraj Hospital, Mahidol University, Bangkoknoi

11030

Northwell Health, Manhasset

19104

Philadelphia VA Medical Center, Philadelphia

33136

University of Miami Schiff Center for Liver Disease, Miami

40002

Srinagarind Hospital, Khon Kaen

40705

Taichung Veterans General Hospital, Taichung

45267

UC Physicians Company, LLC/Division of Digestive Diseases, Cincinnati

50200

Maharaj Nakorn Chiang Mai Hospital, Tha Muang

92105

Research and Education, Inc., San Diego

98104

Harbourview Medical Center, Seattle

169608

Singapore General Hospital, Singapore

00000

The University of Hong Kong, Hong Kong

Sponsors
All Listed Sponsors
lead

Inovio Pharmaceuticals

INDUSTRY

NCT02431312 - Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects | Biotech Hunter | Biotech Hunter